Malin Corporation plc has named David Berman as its new Head of Research & Development (R&D). David joined Immunocore in September 2018 to advance Immunocore's lead asset, IMCgp100, towards commercialisation and progress Immuocore's growing pipeline of T Cell Receptor (TCR) candidates through clinical development. Prior to joining Immunocore, David was most recently Senior Vice President and Head of the AstraZeneca Immuno-oncology (IO) Franchise, responsible for the strategic development and execution of its late-stage IO programme.